Physician profile
Jacob Cox
NPI 1811387061
$6,347.10
in general payments reported to CMS, 2019-2025
13 companies · $779 in 2025
The $779 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $38.09 · 2021: $81.81 · 2022: $1,560 · 2023: $1,562 · 2024: $2,327 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,675 · Grant: $1,300 · Food and Beverage: $1,232 · Honoraria: $460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,675.00 |
| Grant | $1,300.00 |
| Food and Beverage | $1,232.35 |
| Honoraria | $460.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $2,248.86 | 2022-2025 | Stellaris Elite, Stellaris, Xipere |
| Regeneron Pharmaceuticals, INC. | $1,359.05 | 2023-2025 | Eylea Hd |
| Abbvie INC. | $1,122.34 | 2024-2025 | |
| Alimera Sciences, INC. | $460.00 | 2024 | Yutiq, Iluvien |
| Apellis Pharmaceuticals, INC. | $398.65 | 2022-2025 | Syfovre |
| Alcon Vision LLC | $284.71 | 2021-2024 | Constellation |
| Genentech, INC. | $153.34 | 2025 | Susvimo, Vabysmo |
| Astellas Pharma Global Development | $92.08 | 2025 | Izervay |
| Regeneron Healthcare Solutions, INC. | $72.71 | 2024-2025 | Eylea Hd |
| Genentech USA, INC. | $56.79 | 2025 | Vabysmo |
| Johnson & Johnson Surgical Vision, INC. | $38.09 | 2020 | |
| Astellas Pharma US INC | $34.91 | 2025 | Izervay |
| Eyepoint US, INC. | $25.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.